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Word count for abstract: 240 
ABSTRACT 
Context: Breathlessness is a major cause of suffering and distress and little is known about 
the trajectory of breathlessness near death. 
Objectives: To determine the trajectory and clinical-demographical factors associated with 
breathlessness in the last week of life in specialist palliative care. 
Methods: Prospective, longitudinal cohort study using national data in specialist palliative 
care from the Australian Palliative Care Outcomes Collaboration (PCOC). We included 
patients in PCOC who died between 1 July 2013 and 30 June 2014 with at least one 
measurement of breathlessness on a 0−10 numerical rating scale (NRS) in the week before 
death. The trajectory and factors associated with breathlessness were analyzed using 
multivariate random effects linear regression. 
Results: A total 12,778 patients from 87 services (33,404 data points) were analyzed. The 
average observed breathlessness was 2.1 points and remained constant over time. Thirty-five 
percent reported moderate to severe distress (NRS ≥ 4) at some time in their last week. 
Factors associated with higher breathlessness were younger age, male gender, 
cardiopulmonary involvement, concurrent fatigue, nausea, pain, sleeping problems, higher 
Australia-modified Karnofsky Performance Status, and clinical instability in the multivariate 
analysis. Respiratory failure showed the largest association (mean adjusted difference 3.1 
points; 95% confidence interval, 2.8 to 3.4). 
Conclusion: Although breathlessness has been reported to worsen in the last months, the 
mean severity remained stable in the final week of life. In specialized palliative care, one in 
three people experienced significant breathlessness especially in respiratory disease.    
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INTRODUCTION 
More than 50% of people experience breathlessness at the end of life.(1) These people have a 
range of life-limiting illnesses, not limited to cardio-respiratory diseases. Many people at the 
end of life have several clinical conditions that contribute to progressive breathlessness.(1) 
The prevalence and severity of breathlessness at the end of life varies widely between 
individuals with apparently similar disease processes.(2)  
Breathlessness is a feared symptom at the end of life, especially in people with respiratory 
disease.(3) Breathlessness impairs patients’ quality of life, wellbeing, and function.(4, 5)  
For patients and their caregivers, it is a symptom that continuously reminds people of 
impending death.(6) Breathlessness have been reported to worsen in people with advanced 
disease especially in the last months of life despite evidence-based, symptomatic 
treatments.(4, 5, 7) People with worsening breathlessness particularly fear that they may 
suffocate.(7)  
Half of all caregivers perceive that the person for whom they were caring was 
‘uncomfortable’ or ‘very uncomfortable’ in the last two weeks of life.(8) 
Little is known about breathlessness in the last week, including any factors that may help to 
predict higher levels of symptom prevalence or distress.(9, 10) Understanding the temporal 
patterns of breathlessness at the end of life and clinical-demographical factors associated with 
breathlessness could help to improve the quality of care that is offered.   
Previous studies have focused on breathlessness over longer periods, often with few observations in 
the last hours or days of life. From a large, representative, prospectively collected longitudinal 
database, are there factors that a clinician could identify that put people at higher risk of more severe 
breathlessness at the end of life? Such knowledge would be important to ensure optimized symptom 
control.  
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The aim of this study was to describe the patterns of breathlessness by level of distress and 
underlying life-limiting illness in the last week of life and to identify any sub-populations who 
may be at particular risk of more severe breathlessness. The null hypothesis was that there are 
no identifiable  factors associated with worse breathlessness in the last week of life.  
 
METHODS 
Study design and population 
This was a prospective, longitudinal cohort study using data from the Australian Palliative 
Care Outcomes Collaboration (PCOC).(11) PCOC is funded by the Australian Government 
Department of Health and collects point-of-care data in specialist palliative care services 
across Australia including inpatient and community-based care.(11) Data were included from 
all participating services that routinely collected symptom severity data. The database has 
been used in previous reports.(11, 12) 
Inclusion criteria were patients cared for by services registered in PCOC, dying between 1 
July 2013 and 30 June 2014, who had at least one breathlessness measurement during the 
final seven days of life.   
 
Data collection 
Services participating in PCOC (inpatient, consultative, and community settings) provided 
data for each patient’s demographic characteristics, underlying disease, setting of care, and 
clinical assessments at each change in the Palliative Care Phase (herein ‘phase’), with services 
assessing patients each day they are seen. 
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Phase includes four clinically relevant categories that describe each patient’s palliative care 
trajectory: stable; unstable; deteriorating; and terminal. The criteria for the start and end of 
each phase were recently validated and updated, and the latest version were used in this 
study.(12) A new phase was assigned whenever a clinical change required patient/family 
reassessment or modification of the care plan.(11, 12) 
The standardized assessment included functional status (Australia-modified Karnofsky 
Performance Status; AKPS) (13), and distress from each of seven symptoms using the 
Symptoms Assessment Scale (SAS): appetite problems; bowel problems; breathing problems; 
fatigue; nausea; pain; and difficulty sleeping.(14) SAS measures the severity of the distress 
from each symptom over the previous 24 hours on a numerical rating scale (NRS) between 0 
(“absent or no distress”) and 10 (“worst possible distress”).(14) Scores were by self-report if 
possible or by proxy.(15, 16) Some symptom assessments (6%) were recorded using the 
Edmonton Symptom Assessment System (ESAS; 0-10 NRS of severity) due to local routines. 
ESAS assessments were included as a sensitivity analysis including/excluding them yielded 
consistent findings. 
 
Ethical considerations 
The PCOC was approved by the Human Research Ethics Committee of the University of 
Wollongong (approval ID: HE06/045). As routine clinical data were collected, separate 
consent was not required. 
 
Statistical analyses 
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Data were tabulated using frequencies and percentages for categorical variables, mean with 
SD, and median with range or interquartile range for continuous variables with normal and 
skewed distribution, respectively. 
The primary outcome was distress from breathlessness during the seven days before death. 
All measurements for all patients were included in the analysis. Patients with only one 
measurement were included as they contributed to the estimation of the average 
breathlessness level and association for factors that vary between patients. No data were 
imputed. 
Breathlessness was analyzed in two ways: as average scores and as percentages of the distress 
categories: none (NRS 0); mild (NRS 1 to 3); moderate (NRS 4 to 7); and severe (NRS 8 to 
10). (9, 17) Breathlessness over the last seven days of life was explored graphically in relation 
to age, gender, underlying disease (malignant vs. non-malignant), lung disease (defined as 
chronic obstructive pulmonary disease [COPD] or lung cancer), setting of care (hospital vs. 
community), phase, and AKPS. 
Associations with breathlessness (0-10 NRS) were estimated using uni- and multivariate 
random effects linear regression, accounting for repeated measurements.(18) Variables to 
include in the final model were selected based on subject matter knowledge (2, 9, 16, 19) and 
by exploring the associations for potential factors with breathlessness and covariates in the 
model. Time-varying variables were AKPS, symptoms, and phase. Days before death, age, 
and gender were included in all multivariate models. At the final stage, all initial variables 
were entered simultaneously to check that the model estimates were robust. The final model 
included the variables: day before death (0 to 7); male gender (yes/no); age (continuous); 
primary diagnosis (lung cancer, other cancers, cardiovascular disease, respiratory failure, and 
other non-malignant disease); AKPS (continuous, 10 to 100); nausea and pain (0−10 NRS); 
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and phase (stable, unstable, deteriorating, or terminal). For time-varying covariates, we 
estimated the association for differences between patients by regressing on each patient’s 
covariate mean, and the association within patients (longitudinal change between 
measurements) by centering each measurement on the covariate mean for each patient. 
We calculated 95% confidence intervals (CIs) for all estimates. Statistical analyses were 
performed with Stata version 12.1 (StataCorp LP; College Station, TX, USA; 2013). 
 
RESULTS 
We included 12,778 patients from 87 palliative care services across Australia, providing 
33,404 data points during the last week of life. Patient characteristics are shown in Table 1. 
The mean age was 73 (standard deviation [SD], 14) years and 54% were men. Most patients 
had cancer (78%) and the most frequent diagnosis was lung cancer (17%). There were 22,057 
measurements of breathlessness, a mean 1.7 (SD, 0.9) measures per patient (median 1; range 
1 to 8) in the last week. Forty-nine percent of patients had two or more breathlessness 
measurements during the last seven days. The total number of breathlessness measurements 
per day is shown in Table 2. 
 
Reported breathlessness  
The mean reported breathlessness was 2.1 points on a 0-10 NRS (median 0; interquartile 
range 0 to 4) in the last week of life. Breathlessness varied markedly between patients (SD, 
2.7), and also within patients over time (SD, 1.3). Fifty-four percent of people reported 
breathlessness (NRS ≥1) and 35% had moderate to severe levels (NRS ≥ 4) at some time 
during the last week. The observed mean breathlessness from the beginning of the last week 
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of life did not change as death approached (Figure 1), and the time-trends were similar for the 
subgroups based on: age (above vs. below 65 years), gender, primary diagnosis (lung cancer, 
other cancer, respiratory failure, cardiovascular disease, or other non-malignant disease), and 
care setting.  
 
Factors associated with breathlessness 
Table 3 shows factors associated with breathlessness during the last week of life in the 
multivariate model (n = 9,759 patients with non-missing data on all variables; 13,171 
observations). The average reported breathlessness was higher closer to death when adjusted 
for the other variables in the model. Higher breathlessness was also independently associated 
with male gender; younger age; a primary diagnosis lung cancer, respiratory failure, or other 
non-malignant disease; higher functional status, concurrent nausea and pain; and with 
unstable or deteriorating clinical phase. The factor associated with the largest difference in 
breathlessness was respiratory failure, with a mean increase of 3.1 (95% CI, 2.8 to 3.4) points 
compared to people with non-lung cancer, adjusted for the other factors in the model (Figure 
2). Higher levels of fatigue and sleeping difficulty were also independently associated with 
increased breathlessness when added to the final model, mean increase 0.24 (95% CI, 0.22 to 
0.25) and 0.18 (95% CI, 0.16 to 0.21), respectively. They were not included in the final model 
as they were thought to arise mainly as an effect, and not cause, of breathlessness. The 
associations for functional status and concurrent symptoms were similar for differences 
between patients and for changes within patients over time.  
The adjusted change in breathlessness over time did not differ by age, gender, the presence of 
malignancy, or lung involvement. Model estimates remained unchanged independent of 
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whether phase was included or removed from the model. Findings were similar when 
restricting the analyses to patients with two or more breathlessness measurements. 
Patients who increased two or more points of breathlessness distress in the final week were 
more likely to be diagnosed with lung cancer, have higher AKPS, and tended to have higher 
levels of difficulty sleeping, fatigue, and pain compared to other patients (Table 4). 
On the day of dying, the level of breathlessness distress was highest in patients with 
respiratory failure (mean 4.1 points; 95% CI, 3.0 to 5.3), followed by people with lung cancer, 
cardiovascular disease, and other primary diagnoses (Figure 2). 
 
DISCUSSION 
Main findings 
To our knowledge, this is the largest study to date of breathlessness in the final week of 
life.(2, 9, 19) The main findings are that distress from breathlessness is frequently 
encountered but that the population prevalence of 35% and average severity remains stable 
over the last week of life. However, there is wide variation in the individual levels of 
breathlessness. A number of factors were independently associated with higher 
breathlessness: male gender; younger age; lung disease or a non-cancer diagnosis; concurrent 
pain; higher levels of fatigue or nausea; higher rates of sleeping difficulty; better functional 
status; and clinical instability. Lung involvement (by cancer or COPD) was associated with 
the largest increase in breathlessness. 
 
Strengths and limitations 
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Strengths of the present study include its prospective, national, multicenter design; large study 
population; and collection of clinically relevant data on symptom distress using a validated 
measurement tool (14, 20) at point of care in a real-world palliative care setting. The analysis 
explored differences both between individuals and within individuals over time, and evaluated 
a range of clinically relevant factors. 
A limitation of the study is that PCOC collects clinical and symptom data only at each change 
of phase. However, this anchors the measurements to changes in the patient’s clinical 
condition. The phases have been validated and inter-rater reliability was good although 
slightly lower for the deteriorating phase.(12) Changes that are clinically significant are likely 
to trigger a change in phase and therefore to be recorded. The associations with phase in the 
present study have good face validity, with lowest and highest levels of breathlessness in 
stable and unstable phase, respectively. It is acknowledged that individual breathlessness 
trajectories vary and might differ substantially from the group average.(2) An alternative 
approach would have been to classify the individual trajectories using the change in scores 
that is likely to be perceived as clinically important by the patient, such as 1 point on a 0-10 
NRS of chronic breathlessness.(2, 21) That approach may be less feasible in the presence of 
irregular or missing measurements and does not account for random measurement error or for 
systematic differences in determinants of breathlessness between individuals or over time. We 
used mixed effects linear regression which accounts for missing data and repeated 
measurements.(18) Bias from data missing not at random was not supported as findings were 
robust when analyzing only people with two or more measurements during the last week of 
life. Although patients were asked to rate the severity of symptom distress,(14) ratings might 
pertain to overall severity in some patients. Ratings of severity may however reflect mainly 
symptom unpleasantness or distress in advanced disease, as reported in pain.(22) A possible 
limitation is that we lacked data on whether ratings that were reported by a proxy. Patients 
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self-reported whenever possible but proxy ratings are inevitable as people deteriorate and 
become unable to report at end of life. In this setting, proxy reports from carers and palliative 
care professionals may both under- and over-estimate the presence and severity of 
breathlessness but are useful.(15, 16) We also lacked data on which interventions and 
treatments that the patients received. The findings should be interpreted in the context of 
current clinical practice by specialist palliative care services at the end of life. 
 
What this study adds 
The present study extends previous observations in several important ways. Breathlessness 
has been reported to increase as death approaches,(2, 9, 19) but those studies included almost 
entirely populations with cancer with few data points in the last week of life. (2, 9) The 
present larger dataset shows that the mean breathlessness distress remained unchanged at a 
population level in the last week of life. This finding is a robust representation of 
breathlessness in the last week of life and unlike some other studies on the topic (23, 24) 
accounted for repeated measurements. The prevalence and severity of breathlessness were 
consistent with a study during the last month of life in a similar palliative care setting.(9)  The 
lack of a change in intensity or prevalence of breathlessness over the last week of life in the 
present study compared to previous reports would seem to be simply a matter of when in the 
illness trajectory that breathlessness is worst.(19) 
The present study confirms that patients with lung involvement experience markedly higher 
levels of breathlessness distress than do people without lung involvement. (2, 9, 19, 25-31) 
The present study identified a number of patient characteristics that are independently 
associated with higher breathlessness distress in the last week of life. Patients with 
nonmalignant disease and especially lung involvement suffered from markedly higher levels 
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of breathlessness. Airway obstruction, lung infection, pericardial and pleural effusions have 
been associated with increased breathlessness near death,(10) likely mediated through 
impaired gas diffusion in the lungs, increased ventilatory drive, breathing effort, and relative 
ventilator insufficiency.(5) Despite being more symptomatic, patients with advanced 
respiratory disease, and particularly end-stage COPD, may also receive less treatment with 
opioids for breathlessness compared to cancer patients due to fear of respiratory 
depression.(31) The findings of higher breathlessness in people with better functional status 
may be related to higher mobility and hence more exertional breathlessness.  
Interestingly, concurrent negative sensations – fatigue and nausea were independently 
associated with increased breathlessness distress near death. This is consistent with previous 
reports including studies of symptom clusters.(32-35) Fatigue and sleeping difficulty may 
largely be consequences, and not causes, of increasing distress from breathlessness.  The 
presence of concurrent negative emotions have been associated with an increase in the 
affective component of breathlessness − that breathlessness is perceived as more distressing 
or frightening.(36, 37) This could be mediated through a co-activation of similar limbic 
systems involved in the awareness of distressing breathlessness.(36) The question arises 
whether relief of concurrent symptoms could indirectly decrease the severity and distress 
from breathlessness. Optimized treatment of the underlying cause(s) is an important part of 
breathlessness management, including treatment of symptomatic anemia, pleural effusions, 
and airflow obstruction.(27, 38, 39) Relief of concurrent unpleasant symptoms such as nausea 
and pain could be an important approach to relieve the distress from breathlessness. 
 
Implications for research 
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A key question that arises from these findings is what happens to the people with the identical 
diagnoses who are not seen by palliative care services. Are they not referred because their 
level of symptom control is reasonable, or is it even more insufficient? Do symptom control 
rates differ between the inpatient and the community setting?  
It is not clear from this study what was being done to relieve breathlessness. Given that the 
evidence base for the treatment of chronic refractory breathlessness is almost entirely derived 
from people earlier than the last week of life, do the evidence for pharmacological and non-
pharmacological interventions apply to people near death? Understanding the actual 
interventions to deal with breathlessness is important to ensure that the most effective 
therapies are being used. 
 
Implications for clinical practice 
At a health systems level, it has been demonstrated that symptom control can be 
systematically improved.(11) While rates of breathlessness may not increase in the last week 
of life, breathlessness often remains insufficiently controlled. To improve the levels of 
comfort in the last week of life, clinicians need to identify patients with the factors that are 
independently associated with a higher risk of uncontrolled breathlessness in order to do two 
things: focus greater efforts to ensure evidence-based symptom management interventions are 
pro-actively implemented; and to discuss with the patient and his / her family the potential for 
breathlessness to be present so that concerns they have can be addressed. Patients with end-
stage lung disease have particularly high frequency and severity of breathlessness. These 
people deserve close clinical monitoring in order to optimize evidence-based treatments and 
hence reduce distress at the end of life.(40) 
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TABLES 
Table 1. Characteristics of 12,778 patients in specialist palliative care 
Characteristic All 
n (%) 
Age  73 (SD, 14) 
Male gender 6,922 (54) 
Malignant disease (N=12,720) 9,872 (78) 
Primary diagnosis  
Lung cancer 2,195 (17) 
Colorectal cancer 1,168 (9) 
Other gastrointestinal cancer 963 (8) 
Breast cancer 715 (6) 
Neurologic disease 
*
  754 (6) 
Hematological cancer 661 (5) 
Pancreas cancer 614 (5) 
Prostate cancer 552 (4) 
Cardiovascular disease 554 (4) 
Other non-malignancy 422 (3) 
Respiratory failure 380 (3) 
Other diagnoses † 3,742 (29) 
State (no. services) (N=12,720)  
New South Wales / ACT (22) 4,010 (31) 
Queensland (21) 2,255 (18) 
South Australia (12) 914 (7) 
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Tasmania (6) 587 (5) 
Victoria (18) 3,219 (25) 
West Australia (8) 1,793 (14) 
Setting of care (N=12,776)  
Hospital 9,885 (77) 
Community 2,891 (23) 
Phase  
Stable 1,041 (8) 
Unstable 1,503 (12) 
Deteriorating 4,311 (34) 
Terminal 5,923 (46) 
AKPS, median (IQR) (N=12,111) 20 (20-40) 
 
Data presented as n (%) unless otherwise specified. Baseline place of care and phase were for 
the first record and AKPS was for all reports in the last week of life. 
*
 Neurologic disease included stroke, dementia, and neuromuscular disease. 
† 
Other diagnoses included end-stage kidney, liver, multiorgan failure, and other cancers. 
Abbreviations: ACT = Australian Capital Territory; AKPS = Australia-modified Karnofsky 
Performance Status; IQR = interquartile range; SD = standard deviation. 
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Table 2. Breathlessness measurements in 12,778 patients over the last week of life  
Days before death Breathlessness measurements, n 
7 1,610 
6 1,808 
5 2,153 
4 2,548 
3 3,094 
2 3,936 
1 5,145 
0 1,763 
Total 22,057 
The total number of breathlessness measurements per day in the last week of life. Each patient 
could have only one measurement per day. The number of measurements per patient during 
the last week was a mean 1.7 (SD, 0.9; median 1; range 1 to 8). 
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Table 3. Multivariate model of breathlessness in 12,778 patients during the last week of 
life 
Variable Change in mean breathlessness 95% CI P-value 
Day nearer death 0.14 0.12 to 0.17 <0.001 
Male gender 0.12 0.02 to 0.22 0.022 
Age (per y) -0.01 -0.01 to 0.00 0.001 
Primary diagnosis    
Cancer, non-lung Ref   
Lung cancer 1.64  1.46 to 1.74 <0.001 
Cardiovascular 1.40 1.15 to 1.64 <0.001 
Respiratory failure 3.08 2.79 to 3.36 <0.001 
Other non-cancer 0.35 0.20 to 0.49 <0.001 
    
AKPS (per 10 points) 0.22 0.18 to 0.26 <0.001 
Nausea (per point) 0.12 0.09 to 0.14 <0.001 
Pain (per point) 0.17 0.16 to 0.19 <0.001 
Phase    
Stable Ref   
Unstable 0.60 0.42 to 0.77 <0.001 
Deteriorating 0.35 0.19 to 0.52 <0.001 
Terminal -0.04 -0.23 to 0.15 0.690 
 Model intercept   
Intercept 0.30 -0.08 to 0.68 0.117 
Associations with the average breathlessness on a 0-10 numerical rating scale in palliative care 
patients (n=9,759; 13,171 observations) during the last week of life. Associations are estimated using 
multivariate random effects linear regression and are adjusted for all other variables in the model. 
Abbreviations: AKPS = Australia-modified Karnofsky Performance Status; CI = confidence interval; 
IQR = interquartile range; SD = standard deviation. 
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Table 4. Comparison of patients who increased ≥ 2 NRS points in breathlessness 
anytime in the last week of life among 6,207 patients with multiple measurements 
Characteristic Increased ≥ 2 NRS points 
N = 2,886 (46%) 
Other 
N = 3,321 (54%) 
Age 72.5 ± 13.5 73.3 ± 13.4 
Male gender 1,617 (56) 1,782 (54) 
Malignant disease 2,388 (83) 2,716 (82) 
Primary diagnosis   
Cancer, non-lung 1,726 (60) 2,240 (68) 
Lung cancer 662 (23) 476 (14) 
Cardiovascular 125 (4) 97 (3) 
Respiratory failure 102 (4) 58 (2) 
Other non-cancer 261 (9) 437 (13) 
Hospital care 2,337 (81) 2,789 (84) 
AKPS 
*
 30 (20 to 40) 20 (20 to 35) 
Difficulty sleeping * 0.5 (0 to 2.25) 0 (0 to 1.33) 
Fatigue * 4 (2.50 to 5.67) 3 (0 to 5.50) 
Nausea 
*
 0 (0 to 1.00) 0 (0 to 0.67) 
Pain * 2 (0.75 to 3.67) 1.67 (0 to 3.33) 
Data presented as mean ± standard deviation or count (%) unless otherwise stated. Patients in 
the increasing breathlessness group had slightly more lung cancer, lower functional status 
(AKPS), and tended to have higher levels of difficulties sleeping, fatigue, and pain. 
* 
Median score (interquartile range) during follow-up. 
Abbreviations: AKPS = Australia-modified Karnofsky Performance Status; NRS = 0-10 
numerical rating scale of symptom distress.  
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FIGURE LEGENDS 
 
Figure 1: Reported levels of distress from breathlessness in the week before death 
(n=12,778).   
Severity categories were defined as none (NRS 0), mild (NRS 1 to 3), moderate (NRS 4 to 7), 
and severe (NRS 8 to 10). 
Abbreviation: NRS = numerical rating scale. 
 
Figure 2: Mean breathlessness distress by diagnosis group (n=12,778).  
Mean scores on a 0-10 numerical rating scale by diagnosis group, adjusted for gender, age, 
Australia-modified Karnofsky Performance Status, concurrent nausea, pain, and clinical phase 
using random effects linear regression. 
 
 
 
 
 
 
